Did you know that you can now donate to C-Path using the Combined Federal Campaign? Are you a federal employee or retiree? Then GIVE HAPPY to us through the CFC using charity code #28364. One of the great benefits of the CFC is that you can give though payroll deduction or through your retiree annuity, giving a little each pay period and supporting our mission all year long. #CPath #CFC #Donate #DrugDevelopment?
Critical Path Institute (C-Path)
研究服务
Tucson，AZ 8,596 位关注者
Advancing Drug Development. Improving Lives. Together.
关于我们
Critical Path Institute (C-Path) is an independent, nonprofit established in 2005 as a public-private partnership, in response to the FDA’s Critical Path Initiative. C-Path’s mission is to lead collaborations that advance better treatments for people worldwide. Globally recognized as a pioneer in accelerating drug development, C-Path has established numerous international consortia, programs and initiatives that currently include more than 1,600 scientists and representatives from government and regulatory agencies, academia, patient organizations, disease foundations and pharmaceutical and biotech companies. With dedicated team members located throughout the world, C-Path’s global headquarters is located in Tucson, Arizona and C-Path’s Europe subsidiary is headquartered in Amsterdam, Netherlands. For more information, visit c-path.org.
- 网站
-
https://www.c-path.org/
Critical Path Institute (C-Path)的外部链接
- 所属行业
- 研究服务
- 规模
- 51-200 人
- 总部
- Tucson，AZ
- 类型
- 非营利机构
- 创立
- 2005
- 领域
- creating collaborations with regulators, patient advocacy groups and the regulated pharmaceutical industry、accelerated development of safer, new medical products、faster, safer, and smarter medical product development和public private partnership
地点
Critical Path Institute (C-Path)员工
-
Deb Discenza (she/her/hers)
-
Thomas Morel
Global Patient-Centred Outcomes Research & Policy Lead at UCB
-
Huong Huynh Reagan
Regulatory Director | Regulatory endorsements of drug development tools | Cross-functional collaborations | Diverse disease portfolio | Lead people;…
-
Hannah Blau
Data Scientist ? Research Software Engineer ? Listener Extraordinaire ? She who does not let stuff fall through the cracks
动态
-
November marks?Alpha-1 Antitrypsin Deficiency Awareness Month, and C-Path is proud to highlight the critical work being done through its?Critical Path for Alpha-1 Antitrypsin Deficiency consortium. AATD, a rare genetic condition, presents unique challenges, particularly in its?hepatic and pulmonary manifestations. CPA-1 is dedicated to addressing these unmet needs by building an?aggregated database — a resource that integrates data from clinical trials, natural history studies, registries and beyond to inform the development of innovative solutions. At the heart of CPA-1 is its mission to unite industry partners, academic researchers, regulators, patient groups and those with lived experience in a?collaborative public-private partnership. Together, we are fostering alignment, addressing shared challenges, and creating tools that will accelerate advancements in AATD drug development, ensuring brighter futures for those impacted by this condition. Watch patient advocate, Kristin Hatcher, discuss the importance of collaboration in the Alpha-1 space. Kristin is the Pediatric and Rare Liver Diseases Program Director at the Global Liver Institute and a dedicated advocate for people living with alpha-1 antitrypsin deficiency. Learn more about C-Path's CPA-1 program here: https://lnkd.in/gVzvEubJ. #CPath #Alpha1Awareness #DrugDevelopment #DataSharing #GlobalHealth #Collaboration
-
Congratulations to?C-Path's Klaus Romero, CEO, and?Kristen Swingle, President and COO, on being named among the?100 Most Innovative and Influential Healthcare Leaders?in?AZ Big Media’s?Who’s Who in Healthcare for 2025! This recognition highlights their transformative contributions to healthcare innovation and patient-centric advancements. Dr. Romero’s leadership has positioned C-Path as a global authority in regulatory-grade drug development tools, paving the way for groundbreaking approaches in precision medicine and regulatory science. His dedication to fostering collaboration and leveraging cutting-edge technologies continues to accelerate solutions for critical health challenges worldwide. Kristen Swingle’s operational leadership and deep expertise in medical and molecular sciences have been instrumental in advancing C-Path’s mission. Her focus on effective communication and consensus-building ensures that those with lived-experience remain at the heart of every C-Path initiative. Thank you, Klaus and Kristen, for your tireless commitment to transforming drug development and improving lives. This honor is well-deserved! The edition is available now on newsstands and digital; find their profiles and interviews on pg. 40. Full digital issue here: https://lnkd.in/gXvESmrq #CPath #AZBusiness #HealthCare #DrugDevelopment #Leadership #HealthcareInnovation #WhoWhoInHealthcare #Arizona?
-
-
Biomarkers are accelerating drug development for Alzheimer’s disease. Critical Path for Alzheimer Disease is pioneering the way biomarkers are rigorously evaluated to ensure that they can be relied upon for use in clinical trial design. Biomarkers that are expected to predict clinical benefit based on appropriate studies, could change the entire landscape of Alzheimer’s treatment, including moving from reaction to prevention. Visit c-path.org/cpad to read more about the vital role of Biomarkers in Alzheimer’s disease. #CPath #AlzheimersDiseaseAwarenessMonth #CPAD #Biomarkers?
-
-
?New Impact Story? How C-Path's Biomarker Data Repository Brings Patients to the Table to Discuss Biomarkers and Their Impact ? BmDR’s work embodies C-Path’s mission to lead collaborations that accelerate drug development and advance better treatments for people worldwide. C-Path generates solutions to facilitate scientific and regulatory pathways that accelerate the development of therapies for?people with unmet medical needs. C-Path doesn’t develop therapies; C-Path accelerates their development, helps them get to market faster, and helps improve patients’ lives. At a recent BmDR Community Engagement Committee meeting, Dave White detailed the frustrations patients face when treatments take too long to become available. “This takes me back to 2017 when I was with the Kidney Health Initiative, and we were in the midst of co-creating the Kidney Health Initiative’s renal replacement therapy roadmap. One of the Patient Advisory Committee members became so frustrated that she quit because she couldn’t understand why it took so long to be cured and have adequate treatments. We, as a team, didn’t really know how to explain it either. That would have been the perfect time to explain the BmDR ?and what we are trying to develop.” To read more of this impact story, click here: https://lnkd.in/gdin2H29 Glenda V. Roberts, Dave White, Richard Knight, MBA #CPath #DrugDevelopment #Collaboration #PatientFocused #Biomarkers #KidneyDiease #CommunityEngagement #PatientEngagement
-
-
C-Path is proud to share?Vice President of Neurology Diane Stephenson’s?insightful post below and extend our heartfelt congratulations to Diane and all the co-authors of this pioneering manuscript,?“Accelerating Parkinson’s Disease Drug Development with Federated Learning.” This publication represents a significant step forward in leveraging?federated machine learning?to enhance collaboration, maintain patient privacy, and accelerate treatment development for Parkinson’s disease. At the core of this effort is a commitment to innovation and global teamwork — a commitment that Diane so eloquently celebrates in her post. We are inspired by the collaboration between Diane Stephenson, Novartis leaders Amit Khanna, GRAHAM JONES, Laura Gaetano, and the entire team, as well as Diane’s call to action in honor of Carl Ames, a champion for digital health technologies in the fight against PD. Join us in acknowledging the power of partnership in advancing solutions for Parkinson’s disease. Open access to the manuscript here: https://lnkd.in/g3H_KEcW #CPath #ParkinsonsDisease #DrugDevelopment #DigitalHealth #DataSharing #Collaboration
I am reaching out today to share a new pioneering manuscript published last week that speaks to all of those who have been champions for advancing much needed digital health technologies in clinical trials. https://lnkd.in/g9e7dF9Q There is an urgent need for effective treatments for Parkinson’s disease yet the complex and heterogenous pathology, etiology and symptom manifestations has resulted in the need to design, capture and interrogate diverse clinical datasets that span the disease continuum. The publication titled “Accelerating Parkinson’s Disease drug development with federated learning” discusses how federated machine learning approaches that trains algorithms across decentralized data sources can enhance the development of treatments for Parkinson’s Disease. This method allows researchers to collaborate and analyze data from multiple institutions while maintaining patient privacy. It is so rewarding to be partnering with the leaders of Novartis Amit Khanna , GRAHAM JONES and Laura Gaetano who led this manuscript in with urgency and innovation. I am grateful to them for responding to these calls to action 1) my own ask to our CPP 3DT team to be sure that we approach regulators as a global community 2) a call to action from my dear friend Carl Ames, no longer with us after losing his life to PD at the young age of 59. Carl told us ten years ago why he had hope for digital health technologies in his battle with PD: https://lnkd.in/gduiKnNx Thanks to all of my coauthors for collaborating in new ways. By joining hands across the globe, Critical Path Institute is able to embark on new ways to apply our core competencies to delivering much needed drug development tools. Chrystalina Antoniades , Bas Bloem , Camille Carroll , Jesse Cedarbaum , Josh Cosman , David Dexter , Marissa Dockendorf , Jeremy Edgerton , Erkuden Goikoetxea, PhD , Derek Hill , Fay Horak , Elena Izmailova , Tairmae Kangarloo , Dina Katabi , Katie Kopil , Michael Lindemann , Jennifer Mammen , Ken Marek , Kevin McFarthing , Anat Mirelman , Martijn Muller , Gennaro Pagano , Judith Peterschmitt , Jie Ren , Lynn Rochester , Sakshi S. , Andrew Siderowf , Tanya Simuni , Christine Swanson-Fischer , John Wagner, MD, PhD
-
C-Path's Jagdeep Podichetty, PhD, and Nick Henscheid, presented on Fundamentals of Data Science and Machine Learning as part of the Fall 2024 CTS 641A course in the Clinical Translational Sciences Graduate Program at the University of Arizona. The presentation provided an overview of AI/ML principles and their applications in healthcare and drug development. This session highlighted the transformative role of machine learning in advancing medical research and patient care, with a practical focus on building an XGBoost Classification Model to predict breast cancer recurrence. Students gained foundational knowledge and hands-on experience with tools that are shaping the future of healthcare innovation. #CPath #DrugDevelopment #MachineLearning #AI #ML #Collaboration
-
-
The Tucson community is special.?Known to be welcoming, C-Path has had the unwavering support of our local partners since our doors first opened in 2005.?At C-Path, our engagement with the community goes hand-in-hand with fulfilling our mission.?By forging deep connections, we can achieve our mission to lead collaborations that accelerate drug development more effectively and create positive, lasting change. This weekend, C-Pathians participated in one of the city’s most celebrated events, the 41st Perimeter Bicycling - El Tour de Tucson, the renowned cycling race that draws participants from all over the globe. C-Path’s involvement with El Tour kicked off in 2013 and the team has sent riders every year since. As C-Path has grown, so too have the number of C-Pathians and their families that come out to join the other 9,000 cyclists. This year’s event was held this past Saturday, November 23, 2024. The weather was an ideal 76 degrees with partly cloudy skies, and a nice breeze making it the perfect day for a Saturday ride. Thanks to all who participated in this Tucson favorite. Nicholas King, Diane Stephenson, Christine Miller, Ramona Walls, Kristen Swingle, Maaike Everts, Michael Pauley #Tucson #CPath #Collaboration #DrugDevelopment #ElTourdeTucson
-
-
Upcoming webinar:?The Power of Data Sharing and Collaboration Across LGMDs in a Pre-Competitive, Neutral Environment ?? Thursday, December 12 | 11 AM ET This event will feature?Dr. Volker Straub, a renowned neuromuscular genetics expert and Director of the John Walton Muscular Dystrophy Research Centre @ Newcastle University. Dr. Straub will provide an overview of Limb-Girdle Muscular Dystrophies and highlight critical unmet needs in the field. He’ll be joined by a panel of experts: Douglas Sproule?(ML Bio Solutions) Jennifer Levy?(Coalition to Cure Calpain 3) Kat Bryant Knudson?(Speak Foundation) Sophie Olivier?(Atamyo Therapeutics) Cécile Ollivier (C-Path) Together, they’ll explore how the launch of the LGMDs Task Force aims to foster data sharing across LGMD subtypes, drive innovation in drug development, and inspire new researchers to enter the field. What you'll gain: ? Learn about cutting-edge initiatives to address challenges in LGMD research. ?Hear diverse perspectives from advocacy leaders, industry stakeholders, and leading scientists. ?Discover how collaboration in a pre-competitive, neutral environment can accelerate progress for LGMDs. Don’t miss this opportunity to be part of a conversation that could shape the future of LGMD drug development. ?? Register now:?https://lnkd.in/d5EkhkPT Collin Hovinga Alexandre Bétourné, PhD, PharmD, PMP Ramona Belfiore-Oshan Heidi Grabenstatter #CPath #RareDisease #LGMD #limbgirdle #musculardystrophy #drugdevelopment #datasharing #collaboration #taskforce #globalhealth
-
-
Have questions about C-Path's mission? Whether you’re curious about how we collaborate with stakeholders, or how we’re accelerating the development of new treatments, our FAQs section is a valuable resource designed to give you the insights you need. Have a question we haven’t answered yet? Don’t hesitate to reach out—we’re always here to help and provide guidance. You can find more questions and answers on C-Path's website under FAQS: c-path.org/faqs. #C-Path #FAQs #DrugDevelopment